Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Friedemann Paul
With
TAIYO EUROPE
The hypotheses of our study are:
Sunphenon EGCg has an antiinflammatoric effect due to its impact on the T-cell-proliferation and the inhibition of the activity of NF-Kb.
Sunphenon EGCg has a neuroprotective effect due to its antioxidative potence as a radical scavenger.
A 30 month treatment with Sunphenon EGCg is safe and well-tolerated.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Primary or secondary chronic progressive multiple sclerosis (ms)
EDSS 3-8
Age 18-65
You may not be if
Relapsing-remitting ms
Immunodulatoric or immunosuppressive therapy
pretreatment with Mitoxantron, Natalizumab, Rituximab, Azathioprin \<2 month before screening
pretreatment with Glairameracetat or beta-Interferons \<4 weeks before screening
signs of hepatic dysfunction
active ulcus ventriculi or duodeni
neoplasias if not cured \>1 year before screening
Clareo Health | Sunphenon in Progressive Forms of Multiple Sclerosis
